HUNTINGTON BEACH, Calif., July 14, 2005 (PRIMEZONE) -- WayPoint Biomedical Corporation (Pink Sheets:WYPB) has appointed Phill Richer as their Global Director of Sales & Marketing.
Prior to joining WayPoint, Mr. Richer was the Vice President of Sales and Marketing for Teco Diagnostics, a worldwide leader in the Clinical Diagnostics field, with distribution in over 80 countries worldwide. Before working at Teco, Mr. Richer held the Vice President of Sales position for Medical Clinical Consortium, a Los Angeles-based distributor of rapid diagnostic kits, primarily focused on the Drugs of Abuse Market. Mr. Richer has also held management positions with ACON Labs and Sissel USA. With over twenty years experience in International Trade, Mr. Richer was a sitting member on the Southern California Export Council appointed by Ron Brown, former Secretary of Commerce under President Bill Clinton.
According to Bret Hendzel, President and COO of WayPoint, "Phill brings considerable professional experience in strategic planning, sales management and a wealth of international contacts to WayPoint. His extensive industry network will be instrumental to our success as we setup distribution channels and expand into the Diagnostic, Over the Counter, and Point of Care Testing markets. We look forward to his insight, enthusiasm and contributions, as WayPoint increases its global presence."
About WayPoint Biomedical:
WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (Pink Sheets:WYPB), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical visit www.waypointbiomedical.com, www.drinkdetectiveusa.com.
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.